Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial

Table 1

Patient demography at screening.

	Docetaxel alone (𝑛=9)	Gefitinib + docetaxel (𝑛=9)
Age (range; years)	53.1 (35–69)	56.3 (37–67)
Weight/height	70.4 kg/164 cm	70.4 kg/164 cm
Performance status
WHO grade 0	5	4
WHO grade 1	3	4
WHO grade 2	1	1
Previous therapy for metastatic disease
None	1	5
Endocrine therapy	6	3
Antracycline	1	1